2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyOvarian NeoplasmsQuality of LifeConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Ovarian EpithelialEpothilonesFallopian Tube NeoplasmsFallopian TubesFemaleHumansOvarian NeoplasmsPeritoneal NeoplasmsPlatinumConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients
2018
In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers
Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleFolate Receptor 1HumansImmunoconjugatesMaytansineMice, SCIDRetrospective StudiesXenograft Model Antitumor AssaysConceptsEndometrial cancerXenograft modelCell linesTumor cell linesPatient-derived xenograft modelsUterine cancer cell linesAggressive endometrial cancersEndometrial cancer deathsExpression of FRαPrimary USC cell linesRecurrent endometrial cancerReceptor alpha expressionUSC cell linesImpressive antitumor activityMol Cancer TherUSC patientsCancer cell linesMedian survivalCancer deathPDX modelsPreclinical dataUterine cancerComplete resolutionIMGN853Grade 3
2017
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinomaCell Line, TumorCell ProliferationDisease Models, AnimalDrug CombinationsFemaleHumansMaytansineMiceMice, SCIDMiddle AgedOvarian NeoplasmsReceptor, ErbB-2TrastuzumabConceptsHigh HER2/neu expressionHER2/neu expressionEpithelial ovarian cancerHER2/neuAnti-tumor activityEOC cell linesT-DM1Neu expressionChemotherapy-resistant epithelial ovarian cancerLimited anti-tumor activityAntibody-dependent cell-mediated cytotoxicity (ADCC) activityCell linesSuperior anti-tumor activityCombination of trastuzumabLethal gynecologic malignancyEpithelial ovarian carcinomaTumor growth inhibitionEOC xenograftsGynecologic malignanciesPreclinical dataOvarian carcinomaOvarian cancerClinical studiesXenograft modelSingle agent
2011
Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma
Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, Reimers LL, Kuo D, Huang GS, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecologic Oncology 2011, 124: 26-30. PMID: 22055846, PMCID: PMC3787514, DOI: 10.1016/j.ygyno.2011.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarcinosarcomaCisplatinDisease-Free SurvivalDose Fractionation, RadiationFemaleHumansIfosfamideMiddle AgedNeoplasm StagingRadiotherapy, AdjuvantUterine NeoplasmsConceptsDisease-free survivalAddition of cisplatinUterine carcinosarcomaResidual diseasePelvic external beam radiotherapyYear disease-free survivalKaplan-Meier statistical methodAdjuvant pelvic radiationGrade 3/4 neutropeniaGross residual diseaseIfosfamide/cisplatinPhase II trialStage 1 patientsTolerable toxicity profileRare uterine tumorExternal beam radiotherapyAdjuvant settingEfficacious regimenGOG trialsPelvic radiationRecurrent carcinosarcomaMedian followSystemic chemotherapyII trialUterine tumorsPhase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma
Einstein MH, Frimer M, Kuo D, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecologic Oncology 2011, 124: 21-25. PMID: 22035806, PMCID: PMC3681611, DOI: 10.1016/j.ygyno.2011.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinCarcinoma, PapillaryCystadenocarcinoma, SerousDose Fractionation, RadiationDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, AdjuvantUterine NeoplasmsConceptsAdjuvant pelvic radiationCycles of paclitaxelCycles of chemotherapyRadiation therapyPelvic radiationCarboplatin chemotherapyUterine papillary serous carcinomaExtra-uterine diseaseModality adjuvant therapyNon-hematologic toxicitiesPrescribed radiation therapyVisible residual diseasePhase II trialKaplan-Meier methodPapillary serous carcinomaStage 3Stage 1Combination paclitaxelOverall PFSAdjuvant therapyChemotherapy cyclesII trialMedian ageResidual diseaseSerous carcinoma
2009
A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers
Gupta D, Owers RL, Kim M, Kuo DY, Huang GS, Shahabi S, Goldberg GL, Einstein MH. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecologic Oncology 2009, 113: 327-330. PMID: 19307014, PMCID: PMC4451225, DOI: 10.1016/j.ygyno.2009.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHumansMiddle AgedOvarian NeoplasmsSurvival AnalysisTaxoidsTopotecanUterine NeoplasmsConceptsWeekly topotecanClinical benefitOverall survivalOvarian cancerGrade 3 non-hematologic toxicityKaplan-Meier statistical methodNon-hematologic toxicitiesPrior chemotherapy regimensCycles of chemotherapyGrade 3 toxicityMedian overall survivalPhase II studyPhase II trialMajority of patientsEpithelial ovarian cancerOverall response ratePlatinum-resistant tumorsDose delaysEligible patientsRustin criteriaChemotherapy regimensII trialUnacceptable toxicityII studyMedian duration
2006
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clinical Cancer Research 2006, 12: 298-304. PMID: 16397055, PMCID: PMC4039036, DOI: 10.1158/1078-0432.ccr-05-0229.Peer-Reviewed Original ResearchMeSH KeywordsAlkanesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCaspasesCell CycleCell Line, TumorDrug SynergismEnzyme ActivationFemaleHumansImmunohistochemistryLactonesMiceNeovascularization, PathologicOvarian NeoplasmsPaclitaxelPlatelet Endothelial Cell Adhesion Molecule-1PyronesXenograft Model Antitumor AssaysConceptsXenograft-bearing miceOvarian carcinomaTumor regressionCarcinoma cellsHuman ovarian cancer cellsOvarian carcinoma xenograftsOvarian cancer cellsCombination index methodOvarian carcinoma cellsCell cycle distributionTaxol efficacyCarcinoma xenograftsCD31 immunohistochemistryDrug combinationsImmunohistochemical analysisAnimal modelsSingle agentAntiangiogenic effectsLow dosesVivo modelNotable toxicityAntitumor efficacyDrug concentrationsCycle distributionMice